Abstracts tagged "ACPA"

Abstract Number: 2595 • 2015 ACR/ARHP Annual Meeting
Autoantibodies to Citrullinated Fibrinogen, Anti-CCP2 and Anti-MCV Antibodies in Early Rheumatoid Arthritis Patients with Rapid Radiographic Progression at 1-Year
Yannick Degboé¹, Arnaud Constantin², Delphine Nigon³, Gabriel Tobon⁴, Martin Cornillet⁵, Thierry Schaeverbeke⁶, Gilles Chiocchia⁷, Pascale Nicaise-Roland⁸, Leonor Nogueira⁹, Guy Serre^5,10,11, Alain G. Cantagrel¹² and Adeline Ruyssen Witrand^13,14, ¹Rheumatology, Rheumatology Center, Purpan University Hospital, Toulouse, France, ²Inserm U558, Rheumatology Center, Purpan University Hospital, Toulouse, France, ³CHU Purpan, Toulouse, France, ⁴Rheumatology Department, la Cavale Blanche Hospital, Brest, France, ⁵Service de Biologie Cellulaire, C.H.U. Purpan, Toulouse, France, ⁶CHU Bordeaux, Bordeaux, France, ⁷Immunology-Rheumatology, INSERM U1173, paris, France, ⁸Immunology Department, Bichat Claude-bernard, Universitary Hospital, APHP, Paris, France, ⁹Immunology, UMR CNRS 5165, INSERM 1056, Toulouse, France, ¹⁰Cell Biology, Purpan University Hospital, Toulouse, France, ¹¹Unité Différenciation Épidermique et Autoimmunité Rhumatoïde, Unité Mixte de Recherche, INSERM,Toulouse, France, Toulouse, France, ¹²Rheumatology, Centre Hospitalier Universitaire, Toulouse Purpan, Toulouse, France, ¹³Rheumatolgy, CHU Purpan - Hôpital Pierre-Paul Riquet, Toulouse, France, ¹⁴UMR 1027, Inserm, Toulouse, France
Background/Purpose: We compared the ability of anti-CCP2, anti-mutated citrullinated vimentin (anti-MCV) and anti-citrullinated fibrinogen (AhFibA) antibodies to predict 1-year rapid radiographic progression (RRP; total Sharp…
Abstract Number: 786 • 2015 ACR/ARHP Annual Meeting
Anti-Carbamylated Protein Antibodies Identify Systemic Lupus Erythematosus Patients with Erosive Arthritis: Analysis of a Regional Swedish Register
Alf Kastbom¹, Philip Wallin², Michael Ziegelasch¹, Thomas Skogh¹, Leendert Trouw³ and Christopher Sjöwall¹, ¹Department of Clinical and Experimental Medicine, Rheumatology/AIR, Linköping, Sweden, ²Linköping University, Clinical and Experimental Medicine, Sweden, Rheumatology/AIR, Linköping, Sweden, ³Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Articular manifestations affect a majority of patients with systemic lupus erythematosus (SLE), at least at some time during the disease course. Several investigators have…
Abstract Number: 2597 • 2015 ACR/ARHP Annual Meeting
Fine Specificity of Anti-Citrullinated Peptide Antibodies Is Associated with Left Ventricular Mass Index in Rheumatoid Arthritis Patients without Cardiovascular Disease
Laura Geraldino-Pardilla¹, Jon T. Giles², Jeremy Sokolove³, Afshin Zartoshti⁴, WH Robinson⁵ and Joan M. Bathon⁶, ¹Division of Rheumatology, Columbia University College of Physicians & Surgeons, New York, NY, ²Division of Rheumatology, Columbia University, College of Physicians & Surgeons, New York, NY, ³Medicine, VA Palo Alto HealthCare System and Stanford University, Palo Alto, CA, ⁴Rheumatology, Columbia University Medical Center, NY, NY, ⁵Medicine, Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA, ⁶Rheumatology, Columbia University College of Physicians & Surgeons, New York, NY
Background/Purpose: Heart failure (HF) is a leading cause of excess deaths in RA. We previously found an association between left ventricular mass index (LVMI) and…
Abstract Number: 1433 • 2014 ACR/ARHP Annual Meeting
Clinical Characterization of Subclinical Rheumatoid Arthritis-Associated Interstitial Lung Disease
Masaomi Yamasaki, Rheumatology, Shin-Yokohama Yamasaki Clinic, Yokohama, Japan
Background/Purpose Rheumatoid arthritis-associated interstitial lung disease (RA-ILD) is a common manifestation of rheumatoid lung disease. Subclinical RA-ILD is most commonly identified on HRCT imaging. In…
Abstract Number: 408 • 2014 ACR/ARHP Annual Meeting
14-3-3η Auto-Antibody Positivity Informs Better Clinical Outcomes in RA
D. van Schaardenburg¹, Mairead Murphy², Samina Turk³, Walter P. Maksymowych⁴ and Anthony Marotta⁵, ¹Jan van Breemen Research Institute, Amsterdam, Netherlands, ²Augurex Life Sciences Corp., North Vancouver, BC, Canada, ³Reade, Amsterdam, Netherlands, ⁴University of Alberta, Edmonton, AB, Canada, ⁵1423 Dempsey Road, Augurex Life Sciences Corp., North Vancouver, BC, Canada
Background/Purpose We have previously reported pilot data that patients who are only positive for 14-3-3η auto-antibodies (AAb) and negative for the 14-3-3η protein have a…
Abstract Number: 1248 • 2014 ACR/ARHP Annual Meeting
Serologic and Clinical Overlap Between Sarcoidosis and the Rheumatic Autoimmume Diseases
Sabrina Qazi¹ and Marie Claire Maroun², ¹Internal Medicine-Rheumatology, Wayne State University, Detroit, MI, ²Rheumatology, Wayne State University, Detroit, MI
Background/Purpose Sarcoidosis is a systemic inflammatory disorder of unknown etiology, characterized pathologically by noncaseating epithelioid cell granulomas, primarily affecting the lungs, the eye, the skin,…
Abstract Number: 370 • 2014 ACR/ARHP Annual Meeting
Double Positivity of RA Serologies More Prevalent Yet Associated with Clinical Response in Ethnic Minority Patients with Rheumatoid Arthritis
Mercedes Quinones¹, Sharon Dowell², Ignacio Garcia-Valladares³, Gail S. Kerr⁴, Christopher Swearingen⁵, Luis R. Espinoza⁶, Yusuf Yazici⁷, Edward L. Treadwell⁸, Theresa Lawrence Ford⁹, Yvonne Sherrer¹⁰, Angelia Mosley-WIlliams¹¹, Rodolfo Perez Alamino¹², Chunqiao Luo¹³, Akgun Ince¹⁴, Adrian Godoy² and John Amatruda¹⁵, ¹Division of Rheumatology, Howard University Hospital, Washington, DC, ²Division of Rheumatology, Howard University, Washington, DC, ³Immunology and Rheumatology, Hospital General de Occidente, Zapopan, Jal., Mexico, ⁴Rheumatology, Washington DC VAMC, Georgetown and Howard University, Washington, DC, ⁵Pediatrics and Biostatistics, University of Arkansas, Little Rock, AR, ⁶Medicine-Section of Rheum, LSU Medical Center, New Orleans, LA, ⁷Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ⁸Dept Medicine Div of Rheum, East Carolina University, Greenville, NC, ⁹North Georgia Rheumatology Group, PC, Lawrenceville, GA, ¹⁰Rheum/Immunology, Centre Rheum Immunol Arthritis, Fort Lauderdale, FL, ¹¹Rheumatology, Detroit VAMC, Detroit, MI, ¹²internal Medicine, LSUHSC, New Orleans, LA, ¹³University of Arkansas for Medical Sciences, Little Rock, AR, ¹⁴Arthitis Consultants Inc, St. Louis University, St. Louis, MO, ¹⁵Rheumatology, Howard University, Washington, DC
Double Positivity of RA Serologies More Prevalent But Associated with Clinical Response in a Diverse Ethnic Cohort with Rheumatoid ArthritisBackground/Purpose: The presence of both the…
Abstract Number: 1140 • 2014 ACR/ARHP Annual Meeting
Association of Polymorphisms on OPG, RANK and RANKL with ACPA Presence and Erosions: Results of a Meta-Analysis on 1570 Rheumatoid Arthritis Patients from 3 French Cohorts
Adeline Ruyssen Witrand^1,2,3, Sara Scaramuzzino^1,2, Delphine Nigon⁴, Cédric Lukas⁵, Yannick Allanore⁶, Olivier Vittecoq⁷, Thierry Schaeverbeke⁸, Jacques Morel⁹, Jean Sibilia¹⁰, Anne Cambon-Thomsen^1,2, Alain G. Cantagrel¹¹, Philippe Dieude^12,13 and Arnaud Constantin⁴, ¹UMR 1027, Inserm, Toulouse, France, ²UMR 1027, University Paul Sabatier, Toulouse, France, ³Rheumatolgy, CHU Purpan - Hôpital Pierre-Paul Riquet, Toulouse, France, ⁴Rheumatology, CHU Purpan - Hôpital Pierre-Paul Riquet, Toulouse, France, ⁵Immuno-Rhumatologie, Hopital Lapeyronie, Montpellier, France, ⁶Department of Rheumatology, University Paris Descartes and Cochin Hospital, Paris, France, ⁷Rheumatology, Department of Rheumatology, Rouen University Hospital & Inserm 905, Institute for Biomedical Research, University of Rouen, Rouen, France, ⁸Rheumatology, Bordeaux University Hospital, Bordeaux, France, ⁹Department of Rheumatology, Hôpital Lapeyronie, Montpellier, France, ¹⁰Division of Rheumatology, University Hospital of Strasbourg, Strasbourg, France, ¹¹Centre Hospitalier Universitaire de Toulouse, Toulouse, France, ¹²Rheumatology, Rheumatology departement & INSERM U699, Paris Diderot university, APHP, Bichat hospital, Paris, France, ¹³Rhumatologie, Hopital Bichat Claude Bernard, Paris, France
Background/Purpose Rheumatoid Arthritis (RA) is a multifactorial complex disease characterized by the presence of anti-citrullinated peptides antibodies (ACPA) and joints erosions. The mechanisms of bone…
Abstract Number: 362 • 2014 ACR/ARHP Annual Meeting
14-3-3η Early RA Biomarkers: Does Seronegative RA Exist?
Dirkjan van Schaardenburg¹, Walter P. Maksymowych², Maarten Boers³, Samina Turk⁴, Mairead Murphy⁵ and Anthony Marotta⁶, ¹Dr Jan van Breemenstraat 2, Reade, Amsterdam, Netherlands, ²Department of Medicine, University of Alberta, Edmonton, AB, Canada, ³Deapartment of Epidemiology and Biostatistics, Jan van Breemen Research Institute/Reade, Amsterdam, Netherlands, ⁴Reade, Amsterdam, Netherlands, ⁵Augurex Life Sciences Corp., North Vancouver, BC, Canada, ⁶1423 Dempsey Road, Augurex Life Sciences Corp., North Vancouver, BC, Canada
Background/Purpose RF and ACPA are used for early diagnosis and in prediction models for the risk of RA development in arthralgia patients. There remains a…
Abstract Number: 1054 • 2014 ACR/ARHP Annual Meeting
Rheumatoid Factor, Not ACPA, Is Associated with Disease Activity in Rheumatoid Arthritis
Daniel Aletaha¹, Farideh Alasti² and Josef Smolen³, ¹Department of Internal Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ²Department of Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ³PsAID taskforce, EULAR, Zurich, Switzerland
Background/Purpose To investigate the associations of rheumatoid factor (RF) and autoantibodies against citrullinated proteins (ACPA) with rheumatoid arthritis (RA) disease activity.Methods We analyzed the association…
Abstract Number: 361 • 2014 ACR/ARHP Annual Meeting
Citrullinated 14-3-3η Antibodies Are Specific for Early and Established RA and Are Complementary to ACPA
Anthony Marotta¹, Dirkjan van Schaardenburg², Gilles Boire³, Désirée van der Heijde⁴, Robert Landewé⁵, Maarten Boers⁶, C.F. Allaart⁷, Mairead Murphy⁸, Samina Turk⁹, Vivian P. Bykerk¹⁰, Edward Keystone¹¹, Katherine A. Siminovitch¹¹ and Walter P. Maksymowych¹², ¹1423 Dempsey Road, Augurex Life Sciences Corp., North Vancouver, BC, Canada, ²Dr Jan van Breemenstraat 2, Reade, Amsterdam, Netherlands, ³Rheumatology Division, CHUS - Sherbrooke University, Sherbrooke, QC, Canada, ⁴Leiden University Medical Center, Leiden, Netherlands, ⁵Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, ⁶Deapartment of Epidemiology and Biostatistics, Jan van Breemen Research Institute/Reade, Amsterdam, Netherlands, ⁷Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁸Augurex Life Sciences Corp., North Vancouver, BC, Canada, ⁹Reade, Amsterdam, Netherlands, ¹⁰Divison of Rheumatology, Hospital for Special Surgery, New York, NY, ¹¹Mount Sinai Hospital, Toronto, ON, Canada, ¹²Department of Medicine, University of Alberta, Edmonton, AB, Canada
Background/Purpose Citrullination is a post-translational modification whereby arginine (Arg) is deiminated by PAD enzymes to form citrulline (Cit). In RA, current ACPA assays measure the…
Abstract Number: 993 • 2014 ACR/ARHP Annual Meeting
Anti-Citrullinated Proteins Antibodies Promote Synovial Fibroblast Migration in Rheumatoid Arthritis
Meng Sun¹, Vijay Joshua¹, Aase Haj Hensvold¹, Sergiu-Bogdan Catrina², Lars Klareskog³, Vivianne Malmström⁴, Heidi Wähämaa¹ and Anca I Catrina¹, ¹Medicine, Rheumatology Unit, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, ²Molecular Medicine and Surgery, Molecular Medicine and Surgery, Karolinska University Hospital, Karolinska Institute, Stockholm, Sweden, ³Department of Medicine, Rheumatology Unit, Karolinska Institute, Stockholm, Sweden, ⁴Medicine, Rheumatology Unit, Karolinska University Hospital, Solna, Karolinska Institutet, Stockholm, Sweden
Background/Purpose The presence of anti-citrullinated proteins antibodies (ACPAs) in RA is associated with aggressive disease phenotype and bone destruction. As synovial fibroblasts (SFs) are considered…
Abstract Number: 360 • 2014 ACR/ARHP Annual Meeting
88% of Recent Onset Polyarthritis Patients Are Positive for 14-3-3η Markers and 14-3-3η Auto-Antibodies Inform a Favourable Prognosis
Gilles Boire¹, Nathalie Carrier², Artur Jose de Brum-Fernandes³, Patrick Liang⁴, Ariel Masetto⁵, Yuan Gui⁶, Mairead Murphy⁶, Walter P. Maksymowych⁷ and Anthony Marotta⁸, ¹Rheumatology Division, Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, QC, Canada, ²Rheumatology, Universite de Sherbrooke, Sherbrooke, QC, Canada, ³Department of Medicine, Universite de Sherbrooke, Sherbrooke, QC, Canada, ⁴Rheumatology Division, CHUS, Sherbrooke, QC, Canada, ⁵Rheumatology, CHUS, Fleurimont, QC, Canada, ⁶Augurex Life Sciences Corp., North Vancouver, BC, Canada, ⁷Department of Medicine, University of Alberta, Edmonton, AB, Canada, ⁸1423 Dempsey Road, Augurex Life Sciences Corp., North Vancouver, BC, Canada
Background/Purpose The 14-3-3η protein has been described as a mechanistic marker that is detectable in serum during the very early stages of RA development. A…
Abstract Number: 840 • 2014 ACR/ARHP Annual Meeting
Vascular Calcifications on Hand and Wrist Radiographs Are Associated with Cardiovascular Risk Factors, Antigen-Specific Anti-Citrullinated Protein Antibodies, and Mortality in Rheumatoid Arthritis
E. Blair Solow¹, Fang Yu², Geoffrey M. Thiele³, Jeremy Sokolove^4,5, William H. Robinson^6,7, Zachary M. Pruhs³, Kaleb Michaud^8,9, Alan R. Erickson⁹, Harlan Sayles⁹, Gail S. Kerr¹⁰, Angelo L. Gaffo¹¹, Liron Caplan¹², Lisa A. Davis¹³, Grant W. Cannon¹⁴, Andreas M. Reimold¹⁵, Joshua Baker¹⁶, Pascale Schwab^17,18, Daniel Anderson⁹ and Ted R. Mikuls⁹, ¹Internal Medicine, Division of Rheumatic Diseases, UT Southwestern Medical Center, Dallas, TX, ²University of Nebraska Medical Center, Omaha, NE, ³Internal Medicine, Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, ⁴VA Palo Alto Healthcare System and Stanford University, Palo Alto, CA, ⁵Stanford University School of Medicine, Stanford, CA, ⁶VA Palo Alto Health Care System and Stanford University, Palo Alto, CA, ⁷Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA, ⁸National Data Bank for Rheumatic Diseases, Wichita, KS, ⁹Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, ¹⁰Rheumatology, Washington DC VAMC, Georgetown and Howard University, Washington, DC, ¹¹Medicine, Birmingham VA Medical Center and University of Alabama at Birmingham, Birmingham, AL, ¹²Div of Rheumatology, Denver VAMC and Univ of Colorado School of Medicine, Aurora, CO, ¹³Denver VAMC and Univ of Colorado School of Medicine, Aurora, CO, ¹⁴Division of Rheumatology, Salt Lake City VA and University of Utah, Salt Lake City, UT, ¹⁵Rheumatology, Dallas VA and University of Texas Southwestern, Dallas, TX, ¹⁶Medicine/Rheumatology, University of Pennsylvania and Philadelphia VAMC, Philadelphia, PA, ¹⁷Department of Internal Medicine, Division of Rheumatology, Portland VA Medical Center, Portland, OR, ¹⁸Internal Medicine, Division of Arthritis & Rheumatic Diseases, Oregon Health & Science University, Portland, OR
Background/Purpose: Rheumatoid arthritis (RA) is associated with increased mortality due to cardiovascular disease (CVD). Select antigen-specific anti-citrullinated protein antibodies (ACPA) are associated with atherosclerotic…
Abstract Number: 348 • 2014 ACR/ARHP Annual Meeting
Smoking Status Is Associated with Inflammatory Cytokine Profile and Disease Activity: Decreased Inflammation and Disease Improvement with Smoking Cessation?
Jeremy Sokolove¹, Harlan Sayles², Catriona Wagner³, Lauren J. Lahey¹, Geoffrey M. Thiele⁴, William H. Robinson¹, Andreas Reimold⁵, Gail S. Kerr⁶, Grant W. Cannon⁷ and Ted R. Mikuls², ¹VA Palo Alto Healthcare System and Stanford University, Palo Alto, CA, ²Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, ³VA Palo Alto Heatlh Care System and Stanford University, Palo Alto, CA, ⁴Internal Medicine, Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, ⁵Rheumatology, Dallas VA and Univ of TX Southwestern Med Ct, Dallas, TX, ⁶Rheumatology, Washington DC VAMC, Georgetown and Howard University, Washington, DC, ⁷Division of Rheumatology, Salt Lake City VA and University of Utah, Salt Lake City, UT
Background/Purpose: Cigarette smoking is a risk factor for RA and has been associated with increased disease severity and lower rates of disease remission. We examined…

« Previous Page
1
…
7
8
9
10
11
…
13
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].